Literature DB >> 10438367

Cellular oxidation of low-density lipoprotein by Chlamydia pneumoniae.

M V Kalayoglu1, B Hoerneman, D LaVerda, S G Morrison, R P Morrison, G I Byrne.   

Abstract

A spectrum of clinical and epidemiologic studies implicate infectious agents, including Chlamydia pneumoniae, in the pathogenesis of atherosclerosis. The complexity of atherosclerotic disease necessitates examining the role of infection in the context of defined risk factors, such as high levels of native low-density lipoprotein (LDL). Although native LDL does not have atherogenic properties, cellular oxidation of LDL alters the lipoprotein into a highly atherogenic form. In this report, C. pneumoniae and chlamydial hsp60, an inflammatory antigen that was recently localized to atheromas, were found to induce cellular oxidation of LDL. These data provide initial evidence that an infectious agent can render LDL atherogenic and suggest a mechanism whereby C. pneumoniae may promote atheroma development.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10438367     DOI: 10.1086/314931

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  28 in total

1.  cDNA array analysis of altered gene expression in human endothelial cells in response to Chlamydia pneumoniae infection.

Authors:  B K Coombes; J B Mahony
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

2.  Characterization of Chlamydia pneumoniae persistence in HEp-2 cells treated with gamma interferon.

Authors:  L G Pantoja; R D Miller; J A Ramirez; R E Molestina; J T Summersgill
Journal:  Infect Immun       Date:  2001-12       Impact factor: 3.441

3.  Stress response gene regulation in Chlamydia is dependent on HrcA-CIRCE interactions.

Authors:  Adam C Wilson; Ming Tan
Journal:  J Bacteriol       Date:  2004-06       Impact factor: 3.490

4.  Correlation between rises in Chlamydia pneumoniae-specific antibodies, platelet activation and lipid peroxidation after percutaneous coronary intervention.

Authors:  H Kälvegren; J Fridfeldt; P Garvin; L Wind; P Leanderson; M Kristenson; E Kihlström; T Bengtsson; A Richter
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-03-19       Impact factor: 3.267

Review 5.  Infection with Chlamydia pneumoniae as a cause of coronary heart disease: the hypothesis is still untested.

Authors:  J Thomas Grayston; Robert J Belland; Gerald I Byrne; Cho Chou Kuo; Julius Schachter; Walter E Stamm; Guangming Zhong
Journal:  Pathog Dis       Date:  2014-12-04       Impact factor: 3.166

6.  Signaling events in pathogen-induced macrophage foam cell formation.

Authors:  Yazdani B Shaik-Dasthagirisaheb; Samrawit Mekasha; Xianbao He; Frank C Gibson; Robin R Ingalls
Journal:  Pathog Dis       Date:  2016-07-31       Impact factor: 3.166

7.  Chlamydia pneumoniae-induced foam cell formation requires MyD88-dependent and -independent signaling and is reciprocally modulated by liver X receptor activation.

Authors:  Shuang Chen; Rosalinda Sorrentino; Kenichi Shimada; Yonca Bulut; Terence M Doherty; Timothy R Crother; Moshe Arditi
Journal:  J Immunol       Date:  2008-11-15       Impact factor: 5.422

8.  Retinoic acid prevents Chlamydia pneumoniae-induced foam cell development in a mouse model of atherosclerosis.

Authors:  Shinn-Jong Jiang; Lee Ann Campbell; Mark W Berry; Michael E Rosenfeld; Cho-Chou Kuo
Journal:  Microbes Infect       Date:  2008-07-17       Impact factor: 2.700

9.  Association of carotid plaque Lp-PLA(2) with macrophages and Chlamydia pneumoniae infection among patients at risk for stroke.

Authors:  Berna Atik; S Claiborne Johnston; Deborah Dean
Journal:  PLoS One       Date:  2010-06-09       Impact factor: 3.240

10.  Elicitation of reactive oxygen species in Chlamydia pneumoniae-stimulated macrophages: a Ca2+-dependent process involving simultaneous activation of NADPH oxidase and cytochrome oxidase genes.

Authors:  Anthony A Azenabor; Shoua Yang; Godwin Job; Olanrewaju O Adedokun
Journal:  Med Microbiol Immunol       Date:  2005-01       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.